[go: up one dir, main page]

DK3810279T3 - Kombination omfattende anvendelse af en oligopeptidforbindelse og et anti-pd-1- eller pd-l1-antistof til anvendelse til behandling af neoplastiske tilstande - Google Patents

Kombination omfattende anvendelse af en oligopeptidforbindelse og et anti-pd-1- eller pd-l1-antistof til anvendelse til behandling af neoplastiske tilstande Download PDF

Info

Publication number
DK3810279T3
DK3810279T3 DK19734322.1T DK19734322T DK3810279T3 DK 3810279 T3 DK3810279 T3 DK 3810279T3 DK 19734322 T DK19734322 T DK 19734322T DK 3810279 T3 DK3810279 T3 DK 3810279T3
Authority
DK
Denmark
Prior art keywords
antibody
treatment
combination
neoplastic conditions
oligopeptide compound
Prior art date
Application number
DK19734322.1T
Other languages
English (en)
Other versions
DK3810279T5 (da
Inventor
Lars Prestegarden
Original Assignee
Cytovation ASA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytovation ASA filed Critical Cytovation ASA
Publication of DK3810279T3 publication Critical patent/DK3810279T3/da
Application granted granted Critical
Publication of DK3810279T5 publication Critical patent/DK3810279T5/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/162—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from virus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2827—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against B7 molecules, e.g. CD80, CD86
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Zoology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Virology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK19734322.1T 2018-06-19 2019-06-19 Kombination omfattende anvendelse af en oligopeptidforbindelse og et anti-pd-1- eller pd-l1-antistof til anvendelse til behandling af neoplastiske tilstande DK3810279T5 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB1810058.6A GB201810058D0 (en) 2018-06-19 2018-06-19 Combination therapy using a peptide
PCT/EP2019/066295 WO2019243471A1 (en) 2018-06-19 2019-06-19 Combination therapy using a peptide

Publications (2)

Publication Number Publication Date
DK3810279T3 true DK3810279T3 (da) 2023-10-23
DK3810279T5 DK3810279T5 (da) 2024-08-19

Family

ID=63042825

Family Applications (1)

Application Number Title Priority Date Filing Date
DK19734322.1T DK3810279T5 (da) 2018-06-19 2019-06-19 Kombination omfattende anvendelse af en oligopeptidforbindelse og et anti-pd-1- eller pd-l1-antistof til anvendelse til behandling af neoplastiske tilstande

Country Status (13)

Country Link
US (1) US20210154268A1 (da)
EP (1) EP3810279B1 (da)
JP (1) JP7525408B2 (da)
CN (1) CN112566699B (da)
AU (1) AU2019291079A1 (da)
CA (1) CA3103905A1 (da)
DK (1) DK3810279T5 (da)
ES (1) ES2960783T3 (da)
GB (1) GB201810058D0 (da)
IL (1) IL279461A (da)
PL (1) PL3810279T3 (da)
SG (1) SG11202012768XA (da)
WO (1) WO2019243471A1 (da)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112019023992A2 (pt) 2017-05-19 2020-06-16 Wuxi Biologics (Shanghai) Co., Ltd. Anticorpo ou fragmento de ligação ao antígeno do mesmo, seu método de produção, seus usos, bem como molécula de ácido nucleico, vetor de clonagem ou expressão, célula hospedeira, hibridoma, composição farmacêutica e imunoconjugado
GB202000167D0 (en) 2020-01-07 2020-02-19 Cytovation As Composition for treatment of neoplastic lesions

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201001602D0 (en) * 2010-02-01 2010-03-17 Cytovation As Oligopeptidic compounds and uses therof
US11413332B2 (en) 2013-11-11 2022-08-16 Armo Biosciences, Inc. Methods of using interleukin-10 for treating diseases and disorders
KR20180015269A (ko) * 2015-06-24 2018-02-12 이모듈런 테라퓨틱스 리미티드 암 치료에 사용하기 위한 체크포인트 저해제와 마이코박테리움 전체 세포
LT3429618T (lt) 2016-03-16 2024-05-10 Amal Therapeutics Sa Imuninės sistemos patikros taško moduliatoriaus ir komplekso, apimančio į ląsteles prasiskverbiantį peptidą, krovinį ir tlr peptido agonistą, derinys, skirtas naudoti medicinoje

Also Published As

Publication number Publication date
AU2019291079A1 (en) 2021-01-28
ES2960783T3 (es) 2024-03-06
IL279461A (en) 2021-01-31
CN112566699B (zh) 2024-07-05
CA3103905A1 (en) 2019-12-26
JP2021527677A (ja) 2021-10-14
SG11202012768XA (en) 2021-01-28
US20210154268A1 (en) 2021-05-27
JP7525408B2 (ja) 2024-07-30
PL3810279T3 (pl) 2024-02-26
KR20210022669A (ko) 2021-03-03
DK3810279T5 (da) 2024-08-19
EP3810279B1 (en) 2023-09-13
WO2019243471A1 (en) 2019-12-26
CN112566699A (zh) 2021-03-26
EP3810279A1 (en) 2021-04-28
GB201810058D0 (en) 2018-08-08

Similar Documents

Publication Publication Date Title
IL285581A (en) Systems and methods for detecting security incidents across cloud-based application services
EP3768664A4 (en) SHP2 INHIBITORS AND THEIR USES
EP3797124A4 (en) ANTI-RO1 ANTIBODIES AND ITS USE
DK3735295T3 (da) Forbedrede peptidfarmaceutika til behandling af nash og andre lidelser
DK3463498T3 (da) Plasmabaserede film og fremgangsmåder til fremstilling og anvendelse af den samme.
DK3455259T3 (da) Kombination af anti-PD-1-antistoffer og stråling til cancerbehandling
DK4218738T3 (da) Partikeldråbestrukturer og fremgangsmåder til fremstilling og anvendelse af disse
DK3500299T3 (da) Kombination af zanubrutinib med et anti-CD20- eller et anti-PD-1-antistof til anvendelse i behandling af cancer
DK3618928T5 (da) Anti-Sortilin-antistoffer og fremgangsmåder til anvendelse deraf
IL280317A (en) Anti-avb8 antibodies and compositions and uses thereof
DK3939658T3 (da) Substitueret benzopyrrol og strukturelt relaterede komplementinhibitorer
DK4014976T3 (da) Aprocitentan til anvendelse i behandlingen af hypertension og relaterede sygdomme i kombination med valsartan
MA52797A (fr) Inhibiteurs de masp -2 et procédés d'utilisation
DK3773689T3 (da) Antigene peptider til forebyggelse og behandling af kræft
DK3983064T3 (da) COT-modulatorer og fremgangsmåder til anvendelse deraf
DK3860990T3 (da) Inhibitorer for YAP/TAZ-TEAD interaktion og disses anvendelse ved behandlingen af cancer
DK3293201T3 (da) Kombinering af adenovirus og checkpoint-inhibitorer til behandling af cancer
DK3807316T3 (da) Sammensætninger og fremgangsmåder til behandling af cancer
DK3743447T3 (da) B7-H4-antistoffer og fremgangsmåder til anvendelse deraf
DK3790879T3 (da) Triazolopyrimidinforbindelser og deres anvendelse til behandling af kræft
EP4039704A4 (en) Anti-pd-1 antibody and use thereof
EP3727374A4 (en) COMBINATION OF AN ANTI-PD-L1 ANTIBODY AND AN IDO1 INHIBITOR FOR THE TREATMENT OF CANCER
IL282478A (en) Materials and methods for treating cancer
IL282041A (en) Egfr inhibitors for treating keratodermas
DK3529274T3 (da) Monoklonalt antistof og fremgangsmåde til anvendelse til behandling af lupus